Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute.

Hainsworth JD, Rubin MS, Spigel DR, Boccia RV, Raby S, Quinn R, Greco FA.

J Clin Oncol. 2013 Jan 10;31(2):217-23. doi: 10.1200/JCO.2012.43.3755. Epub 2012 Oct 1.

PMID:
23032625
2.

A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile.

Hainsworth JD, Schnabel CA, Erlander MG, Haines DW 3rd, Greco FA.

Clin Colorectal Cancer. 2012 Jun;11(2):112-8. doi: 10.1016/j.clcc.2011.08.001. Epub 2011 Oct 14.

PMID:
22000811
3.

Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation.

Varadhachary GR, Talantov D, Raber MN, Meng C, Hess KR, Jatkoe T, Lenzi R, Spigel DR, Wang Y, Greco FA, Abbruzzese JL, Hainsworth JD.

J Clin Oncol. 2008 Sep 20;26(27):4442-8. doi: 10.1200/JCO.2007.14.4378.

PMID:
18802157
4.

Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care.

Hainsworth JD, Greco FA.

Virchows Arch. 2014 Apr;464(4):393-402. doi: 10.1007/s00428-014-1545-2. Epub 2014 Feb 1. Review.

PMID:
24487792
5.

Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review.

Pentheroudakis G, Greco FA, Pavlidis N.

Cancer Treat Rev. 2009 May;35(3):221-7. doi: 10.1016/j.ctrv.2008.10.003. Epub 2008 Nov 28. Review.

PMID:
19046817
6.

Molecular diagnosis of the tissue of origin in cancer of unknown primary site: useful in patient management.

Greco FA.

Curr Treat Options Oncol. 2013 Dec;14(4):634-42. doi: 10.1007/s11864-013-0257-1. Review.

PMID:
23990214
7.

Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction.

Greco FA, Spigel DR, Yardley DA, Erlander MG, Ma XJ, Hainsworth JD.

Oncologist. 2010;15(5):500-6. doi: 10.1634/theoncologist.2009-0328. Epub 2010 Apr 28.

8.

Overview of various techniques/platforms with critical evaluation of each.

Agwa E, Ma PC.

Curr Treat Options Oncol. 2013 Dec;14(4):623-33. doi: 10.1007/s11864-013-0259-z. Review.

PMID:
24243164
9.

Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology.

Greco FA, Lennington WJ, Spigel DR, Hainsworth JD.

J Natl Cancer Inst. 2013 Jun 5;105(11):782-90. doi: 10.1093/jnci/djt099. Epub 2013 May 2.

PMID:
23641043
10.

Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance).

Yoon HH, Foster NR, Meyers JP, Steen PD, Visscher DW, Pillai R, Prow DM, Reynolds CM, Marchello BT, Mowat RB, Mattar BI, Erlichman C, Goetz MP.

Ann Oncol. 2016 Feb;27(2):339-44. doi: 10.1093/annonc/mdv543. Epub 2015 Nov 16.

11.

Cancer of unknown primary site: evolving understanding and management of patients.

Greco FA.

Clin Adv Hematol Oncol. 2012 Aug;10(8):518-24. Review.

PMID:
23073050
12.

Capecitabine and oxaliplatin as second-line treatment in patients with carcinoma of unknown primary site.

Møller AK, Pedersen KD, Abildgaard J, Petersen BL, Daugaard G.

Acta Oncol. 2010 May;49(4):431-5. doi: 10.3109/02841861003649240.

PMID:
20235750
13.

Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology Research Consortium.

Hainsworth JD, Spigel DR, Burris HA 3rd, Shipley D, Farley C, Macias-Perez IM, Barton J, Greco FA.

Cancer. 2010 May 15;116(10):2448-54. doi: 10.1002/cncr.25029.

14.

Poorly differentiated neoplasms of unknown primary site: diagnostic usefulness of a molecular cancer classifier assay.

Greco FA, Lennington WJ, Spigel DR, Hainsworth JD.

Mol Diagn Ther. 2015 Apr;19(2):91-7. doi: 10.1007/s40291-015-0133-8.

PMID:
25758902
15.

[Comparing immunohistochemical diagnosis of cancer of unknown primary with gene expression-based tumor classification].

Morawietz L, Floore A, Stork-Sloots L, Folprecht G, Buettner R, Rieger A, Dietel M, Huebner G.

Pathologe. 2009 Dec;30 Suppl 2:168-72. doi: 10.1007/s00292-009-1194-4. German.

PMID:
19756615
16.

Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.

Ross JS, Wang K, Gay L, Otto GA, White E, Iwanik K, Palmer G, Yelensky R, Lipson DM, Chmielecki J, Erlich RL, Rankin AN, Ali SM, Elvin JA, Morosini D, Miller VA, Stephens PJ.

JAMA Oncol. 2015 Apr;1(1):40-9. doi: 10.1001/jamaoncol.2014.216.

PMID:
26182302
17.

Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site.

Hainsworth JD, Spigel DR, Thompson DS, Murphy PB, Lane CM, Waterhouse DM, Naot Y, Greco FA.

Oncologist. 2009 Dec;14(12):1189-97. doi: 10.1634/theoncologist.2009-0112. Epub 2009 Dec 4.

18.

Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary.

Varadhachary GR, Spector Y, Abbruzzese JL, Rosenwald S, Wang H, Aharonov R, Carlson HR, Cohen D, Karanth S, Macinskas J, Lenzi R, Chajut A, Edmonston TB, Raber MN.

Clin Cancer Res. 2011 Jun 15;17(12):4063-70. doi: 10.1158/1078-0432.CCR-10-2599. Epub 2011 Apr 29.

19.
20.

Identification of tissue of origin in carcinoma of unknown primary with a microarray-based gene expression test.

Monzon FA, Medeiros F, Lyons-Weiler M, Henner WD.

Diagn Pathol. 2010 Jan 13;5:3. doi: 10.1186/1746-1596-5-3.

Supplemental Content

Support Center